CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Omalizumab

Omalizumab

Last Updated: April 18, 2005

Result type: Reports

Project Number: SR0035-000

Product Line: Reimbursement Review

Generic Name: Omalizumab

Brand Name: Xolair

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Therapeutic Area: Asthma, severe persistent

Indications: Asthma, severe persistent

Submission Type: Initial

Project Status: Cancelled

Omalizumab

Files